Selection bias

Self-Esteem of Kids with Short Stature Tied to Social Supports, Not Height

Retrieved on: 
måndag, juni 12, 2023
The Journal of Pediatrics, Male, Body composition, Pfizer, CHOP, Parent, Friends, Growth hormone, Social support, Quality of life, Philadelphia, Quality, GH, Science, Journal, MD, Collection, Selection bias, Manuscript, DOI, Growth, Hospital, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Growth hormone deficiency, NIH, Caregiver, Female, Children's Hospital of Philadelphia, Nursing, Birth control, Toy, Pediatrics, Child

PHILADELPHIA, June 12, 2023 /PRNewswire/ -- Challenging the assumption that short stature negatively impacts children and adolescents' self-esteem, a new study by researchers at Children's Hospital of Philadelphia (CHOP) has found that in otherwise healthy short youth, quality of life and self-esteem are associated with coping skills and how supported they feel and not the degree of their short stature. The findings were published in The Journal of Pediatrics.

Key Points: 
  • "But our data show that self-esteem among short youth is tied to social support networks and adaptive coping strategies, not their stature.
  • However, its use has expanded to those with normal GH production who are short for their age, with the sole aim of augmenting height, based on the premise that short stature is debilitating and that height increases lead to improved quality of life.
  • First, children of taller parents may be told their short stature is temporary, given the height of the parents.
  • Short parents who view their own short stature as non-problematic may be less likely to seek care for their child's short stature, whereas short parents who are unhappy about their own height may be more inclined to express negative messaging about short stature and seek medical care for their child.

New Guide from Consilium Helps Manufacturing CEOs Build an Effective Sales Tech Stack

Retrieved on: 
onsdag, maj 10, 2023
Forecasting, Marketing, VPS, Frustration, ERP, Selection bias, Consilium, CRM, Software, Sales, Management

IPSWICH, Mass., May 10, 2023 /PRNewswire-PRWeb/ -- Industrial manufacturers and machinery builders often have very complex sales cycles, working with large buying teams over long projects. But they often fail to build the necessary sales tech stack to help them adequately manage those complexities, improve buyer experience, boost sales efficiency, and increase revenue.

Key Points: 
  • But they often fail to build the necessary sales tech stack to help them adequately manage those complexities, improve buyer experience, boost sales efficiency, and increase revenue.
  • Consilium's new Guide to Building the Right Sales Tech Stack covers the full evaluation, justification, selection, and implementation process.
  • Sales process and methodology are casually disregarded because they're not firmly embedded in the sales tech stack.
  • Consilium's Guide to Building an Effective Sales Tech Stack is the perfect overview to assist with marketing and sales collaboration, executive study and planning, board of directors familiarization, and coordination between management, finance, sales, IT, and marketing.

Highly Anticipated Omnipod® 5 Real-World Evidence to be Presented at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Retrieved on: 
tisdag, februari 21, 2023
Medical Devices, Health, Diabetes, Health Technology, Pharmaceutical, Biotechnology, ABCD, Success, Tubeless tire, Insulin, Doctor of Philosophy, University, Patient, CE marking, Glucose, Corporation, University of Colorado School of Medicine, Prince Sultan Advanced Technology Research Institute, RN, CET, Automated insulin delivery system, Treatment, Research, United Kingdom, Algorithm, International Conference on Nuclear Disarmament, Oslo, 2008, MDR, Associate professor, Medical device regulation, Stanford School, Colorado School of Public Health, Stanford University School of Medicine, University of Nottingham, AID, Conference, Type 2 diabetes, Emory University, Selection bias, Medical director, Data, ATTD, Pharmaceutical industry, Nursing, Medical device, Dietary supplement, FRACP

“With this large sample and limited selection bias, we see strong time in target range and minimal time below range, exceeding glycemic targets on average.

Key Points: 
  • “With this large sample and limited selection bias, we see strong time in target range and minimal time below range, exceeding glycemic targets on average.
  • A recent investigator-initiated feasibility study evaluated the use of automated insulin delivery (AID) with remote glucose monitoring in a hospital setting.
  • There will also be additional research presented on Insulet’s Omnipod DASH® and Omnipod® Insulin Management System.
  • The Omnipod booth will be open throughout the conference and the team will be available to discuss Omnipod products with healthcare providers and other ATTD registrants.

Large Study Identifies Risk Factors in Children with Chronic Kidney Disease

Retrieved on: 
måndag, februari 6, 2023
Clinical Journal of the American Society of Nephrology, Chronic kidney disease, Nemours Children's Hospital, Delaware, MSCE, DOI, PCORI, Kidney, Bangladesh Technical Education Board, Selection bias, National Pediatric Research Network Act of 2013, CKD, EGFR, Proteinuria, Patient, Hospital, Division, National Institute of Diabetes and Digestive and Kidney Diseases, Digestive, Research, Cohort (statistics), Male, Risk, Glomerular filtration rate, Hypertension, CHOP, Children's Hospital of Philadelphia, Kidney disease, EHR, Disease, FDA, Dialysis, Urine, Society, Blood pressure, Philadelphia, Cancer, Nursing, Pharmaceutical industry, Child, Nephrology, MD

PHILADELPHIA, Feb. 6, 2023 /PRNewswire/ -- Chronic kidney disease (CKD) in children is rare, which makes it difficult to study and leaves major gaps in the quantity and quality of evidence that informs the care of pediatric patients with the condition. Even the largest prospective studies are limited in their usefulness, as they are constrained by selection bias and relatively small sample sizes for different causes and courses of the disease.

Key Points: 
  • "The overarching goal of this project was to demonstrate that real world EHR data can be used to model kidney function decline in children.
  • Chronic kidney disease in children is rare and as such there are few high-quality studies that inform clinical decision making," said Caroline Gluck, MD, physician, Division of Nephrology at Nemours Children's Health, Delaware.
  • This study can also serve as a roadmap for use of EHR data networks to adequately power the study of rare disease."
  • "Evaluating Kidney Function Decline in Children with Chronic Kidney Disease Using a Multi-Institutional Electronic Health Record Database," Clinical Journal of the American Society of Nephrology, online January 17, 2023, DOI: 10.2215/CJN.0000000000000051

New Real-World Data Presented at OPTIONS XI Show Cell-Based and MF59®-Adjuvanted Influenza Vaccines Can Reduce the Burden of Seasonal Influenza on Hospitals and Health Systems

Retrieved on: 
måndag, september 26, 2022
Center, Delta, Exhibition, Bed, Society, Patient, Immunodeficiency, Pneumonia, CDC, Emergency, Stroke, Influenza vaccine, Research, Myocardial infarction, Disease, CSL Limited, QALY, MPH, CSL, RCT, ASX, Hospital, COVID-19, Selection bias, Knowledge, Antibody, Influenza, Doctor of Philosophy, Ageing, Observational study, RWE, Haemophilia, CSL Behring, Population, Degenerative disease, 2022–23 UEFA Nations League, Immunization, Neve Ativ, Vaccine, Public health, Korea Disease Control and Prevention Agency, Health, Incidence, Control, Vaccination, MF59, Impact, ICU, Meta-analysis, Randomized controlled trial, Death, Biotechnology, R, RVE, Omicron, MD

The data were presented at OPTIONS for the Control of Influenza XI (OPTIONS XI), being held in Belfast, United Kingdom, from September 26-29, 2022.

Key Points: 
  • The data were presented at OPTIONS for the Control of Influenza XI (OPTIONS XI), being held in Belfast, United Kingdom, from September 26-29, 2022.
  • RWE is a complement to randomized controlled trial (RCT) research, assessing influenza vaccine innovation effectiveness on a continual basis and providing an ever-growing data set on real-world outcomes.
  • Real-World Effectiveness of MF59-Adjuvanted Influenza Vaccine in Preventing Hospitalizationsin Adults 65 Years During the 2019-2020 U.S.
  • No difference was observed between the two types of vaccines in hospitalizations related to pneumonia, myocardial infarction or ischemic stroke.

New Data at OPTIONS XI Conference Highlight Burden of Seasonal Influenza on Health Systems and the Need for Increased Vaccination Rates

Retrieved on: 
måndag, september 26, 2022
Center, Virus, World, Bed, Pressure, Outcome, Patient, Immunodeficiency, Oral, CDC, Disease, Season, CSL Limited, MPH, CSL, ASX, Profile, COVID-19, Selection bias, Organization, Antibody, Urinary tract infection, Veneto, Ageing, Hospital, Haemophilia, CSL Behring, Population, Degenerative disease, Ministry of Women and Vulnerable Populations, Vaccine, Korea Disease Control and Prevention Agency, WHO, Incidence, Control, World Health Organization, Vaccination, ER, Risk, Death, Biotechnology, R, Health insurance, EU, Influenza, MD, Epidemiology, ICU

The data are being presented in oral and poster sessions at OPTIONS for the Control of Influenza XI (OPTIONS XI), being held in Belfast, United Kingdom, from September 26-29, 2022.

Key Points: 
  • The data are being presented in oral and poster sessions at OPTIONS for the Control of Influenza XI (OPTIONS XI), being held in Belfast, United Kingdom, from September 26-29, 2022.
  • This will become even more important in a world where COVID-19 and influenza are likely to continue co-circulating."
  • "8
    As a global leader in influenza protection, CSL Seqirus recognizes its responsibility to help reduce the burden of influenza on health systems and communities, including vulnerable populations like children, around the world.
  • In the region of Italy for which hospitalization data was available, 12,416 influenza cases were reported from January 2017 to March 2020.

Verana Health to Present Abstract at American Statistical Association's Biopharmaceutical Section Regulatory-Industry Statistics Workshop

Retrieved on: 
måndag, september 19, 2022
MPH, American Academy, American Statistical Association, ASA, Selection bias, FDA, Research, Laika (EHR testing framework), Data management, Machine Intelligence Research Institute, Industry, Health information management, Missing data, Patient, ICD, DR, American Academy of Neurology, Technology, Quality of life, Knowledge Organization (journal), Severe cognitive impairment, American Urological Association, Solution, HCP, Doctor of Philosophy, International Classification of Diseases, Record, Diabetic retinopathy, Method, HCPS, SAN, Medicine, American Academy of Ophthalmology, Health, HIV disease progression rates, Electronic health record, EHR, Pharmaceutical industry, Medical device, Ophthalmology

SAN FRANCISCO, Sept. 19, 2022 /PRNewswire/ -- Verana Health®—a digital health company elevating quality in real-world data—will present an abstract at the American Statistical Association's (ASA) Biopharmaceutical Section Regulatory-Industry Statistics Workshop on Sept. 21 in Rockville, Md.

Key Points: 
  • SAN FRANCISCO, Sept. 19, 2022 /PRNewswire/ -- Verana Health a digital health company elevating quality in real-world datawill present an abstract at the American Statistical Association's (ASA) Biopharmaceutical Section Regulatory-Industry Statistics Workshop on Sept. 21 in Rockville, Md.
  • A team of nine Verana Health researchers sought to understand the mechanism of missingness for DR disease severity.
  • Verana Health is a digital health company elevating quality in real-world data.
  • Using its clinician-informed and artificial intelligence-enhanced VeraQpopulation health data engine, Verana Health transforms structured and unstructured healthcare data into curated, disease-specific data modules, Qdata.

New Data Supports the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Reducing Influenza-Related Hospitalizations and Healthcare Costs in Older Adults

Retrieved on: 
tisdag, december 7, 2021
RWE, Risk, Influenza vaccine, Population, Hospital, Disease, CSL, Haemophilia, European Scientific Cooperative on Phytotherapy, Economy, VAERS, Vaccine, CSL Behring, Antibody, Muscle weakness, Allergy, World, Event-driven architecture, Health, Influenza, Patient, Life expectancy, Selection bias, ASX, MF59, Conference, CDC, World Health Organization, Pablo de Olavide University, R, Season, Ageing, Society, FDA, Vaccination, TIV, Guillain–Barré syndrome, Degenerative disease, Research, Biotechnology, Immune system, MD, Immunodeficiency, Neve Ativ, WHO, Health insurance, Pharmaceutical industry, Dietary supplement

Individual study limitations may include: retrospective analyses, a potential lack of laboratory confirmed influenza, and varying data sources.

Key Points: 
  • Individual study limitations may include: retrospective analyses, a potential lack of laboratory confirmed influenza, and varying data sources.
  • As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.
  • FLUAD (Influenza Vaccine, Adjuvanted) and FLUAD QUADRIVALENT (Influenza Vaccine, Adjuvanted)
    What are FLUAD and FLUAD QUADRIVALENT?
  • To learn more, talk about FLUAD and/or FLUAD QUADRIVALENT with your healthcare provider or pharmacist.

Seqirus Presents New Real-World Evidence Supporting Effectiveness of Differentiated Seasonal Influenza Vaccine Technologies at ISIRV-WHO Virtual Conference 2021

Retrieved on: 
tisdag, oktober 19, 2021
ASX, Cohort study, Immune system, Allergy, WHO, Influenza, CDC, Death, MD, RWE, COVID-19, RVE, Pharmacy, Antibody, Centre de coopération internationale en recherche agronomique pour le développement, Guillain–Barré syndrome, Doctor of Philosophy, TNT, Ageing, Disease, Haemophilia, Muscle weakness, International Society, Vaccine, Selection bias, CSL Behring, Vaccination, R, Event-driven architecture, Patient, Conference, Neve Ativ, CSL, Adult, Population, Immunodeficiency, Degenerative disease, Health, Hospital, Health insurance

SUMMIT, N.J., Oct. 19, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced new real-world evidence (RWE) supporting the effectiveness of its cell-based and adjuvanted seasonal influenza vaccines.

Key Points: 
  • SUMMIT, N.J., Oct. 19, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced new real-world evidence (RWE) supporting the effectiveness of its cell-based and adjuvanted seasonal influenza vaccines.
  • "These retrospective studies, which include over 10 million vaccinated U.S. individuals, build on existing RWE in evaluating the effectiveness of influenza vaccines in real-world settings.
  • "These data support that our vaccines can help reduce IRMEs and minimize the burden of influenza, among children and older populations."
  • As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.

Seqirus Presents New Real-World Evidence Demonstrating Effectiveness of Cell-Based and Adjuvanted Seasonal Influenza Vaccines at IDWeek 2021

Retrieved on: 
onsdag, september 29, 2021
Vaccination, RWE, Immunodeficiency, Vaccine, Pressure, Muscle weakness, RVE, Neve Ativ, CSL, Hospital, Patient, Allergy, Adjuvant, MD, Influenza, Guillain–Barré syndrome, CDC, Immune system, CSL Behring, Selection bias, Antibody, Ageing, Disease, ASX, Risk, Degenerative disease, Population, Haemophilia, R, Safety, Investment, Doctor of Philosophy

These analyses will be presented today at the virtual IDWeek 2021 conference.

Key Points: 
  • These analyses will be presented today at the virtual IDWeek 2021 conference.
  • "These data further underscore the public health benefits of innovative technologies, including cell-based and adjuvanted technologies, in producing seasonal influenza vaccines."
  • "We continue making critical R&D investments to measure how our influenza vaccines perform in real-world settings and to advance next-generation technology platforms thathelp safeguard people and communities from influenza."
  • As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.